Larry Biegelsen has given his Buy rating due to a combination of factors, primarily focusing on the recent regulatory approval of Stryker's MAKO Shoulder Application. This approval aligns with Stryker's expectations to secure clearance by the end of the year, positioning the company to target the substantial reverse shoulder market, which constitutes approximately 65% of the market. Additionally, the MAKO Shoulder will be compatible with Stryker's existing implants and integrate Blueprint for pre-operative planning, enhancing its utility. Stryker's expanding MAKO product lineup, which now includes clearances for knees, hips, spine, and shoulders, enhances its attractiveness to ambulatory surgical centers, contributing to the positive outlook reflected in Biegelsen's rating.